Brief: Mateon Therapeutics Announces Positive Clinical Study Results For Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine
23/12/2019 20:52
Dec 23 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON THERAPEUTICS INC - ANNOUNCES POSITIVE CLINICAL
STUDY
RESULTS FOR ITS LEAD ANTI-LEUKEMIA DRUG COMBRETASTATIN A1 PLUS
CYTARABINE IN ADULT PATIENTS WITH RELAPSED ACUTE MYELOID
LEUKEMIA
Source text for Eikon: ID:nGNX5wrz80
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas